F-star Presents New Data on OX40/CD137 Tetravalent Bispecific Antibody at the SITC 2019 Annual Meeting
F-star Therapeutics (“F-star”), a clinical-stage biopharmaceutical company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific (mAb2™) antibodies, today announces that new preclinical data on FS120, a mAb² product candidate targeting OX40 and CD137, will be presented at the Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting in National Harbor, Maryland, United States, being held from 06 - 10 November 2019.
FS120 is a potentially best-in-class dual agonist that has the potential to overcome cancer resistance by simultaneously engaging OX40 (CD134, TNFRSF4) and CD137 (4-1BB), two receptors found on the surface of tumor-infiltrating lymphocytes. Targeting this class of receptors using bispecific tetravalent binding mobilizes multiple arms of the immune system, which research shows is essential for eliminating tumors. F-star’s preclinical data demonstrated that FS120’s crosslink-dependent approach has the potential to provide therapeutic benefit, for example in combination with checkpoint antagonists, and reverse T cell exhaustion in immunosuppressive tumor environments.
Neil Brewis, CSO of F-star said “Recent clinical trials involving agonist molecules have reported that a meaningful anti-cancer response is often associated with liver toxicity, in line with preclinical observations. F-star’s OX40/CD137 mAb² antibody is showing preclinical evidence that an effective tumor-killing response can be decoupled from liver inflammation. We look forward to progressing FS120 into the clinic as we aim to potentially improve treatment outcomes for patients with difficult-to-treat cancers.”
Some CD137 agonist antibodies have been shown to induce adverse effects either in clinical or in preclinical studies as they constitutively activate T cells and thus release cytotoxic immunity outside of the tumor. In contrast, FS120 is designed to mitigate off-target toxicity through conditional, crosslink-dependent activation upon binding to both OX40 and CD137, which are predominantly present on T cells in the tumor microenvironment.
F-star expects to submit an IND application for FS120 during the fourth quarter of 2019.
Details of the poster are below:
Crosslink-independent CD137 agonism is associated with liver inflammation
Abstract poster number: P775
Poster hall location: Prince George AB
Poster hall hours: 07:00 to 20:00 on Friday 08 November 2019
Poster presentation hours: 12:30 to 14:00 and 18:30 to 20:00 on Friday 08 November 2019
- ENDS -
F-star is a clinical-stage immuno-oncology company singularly focused on transforming the lives of patients with cancer through the development of its innovative tetravalent mAb2 bispecific antibodies. With four distinct binding sites in a natural human antibody format, F-star believes its proprietary approach will overcome many of the challenges facing current immuno-oncology therapies. F-star’s vision is to transform the treatment of cancer through the development of differentiated and well-tolerated mAb2 bispecific antibodies, which are designed to simultaneously address multiple immune evasion pathways that limit the effect of current immuno-oncology therapies.
mAb2™ is a trademark of F-star.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
For investor enquiries
VP Investor Relations & Communications
+1 240 543 7970
Consilium Strategic Communications
Chris Gardner, Sue Stuart, David Daley
Tel: +44 (0)20 3709 5700
For media enquiries
+44 (0)1223 948 094
+44 (0)7392 080 279
Catherine London, US President
Tel: +1 917-763-2709
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pharmsynthez PJSC Secures RUB 800m With LDA Capital24.6.2021 08:00:00 EEST | Press release
Innovative Russian pharmaceutical developer, Pharmsynthez PJSC (MOEX:LIFE), and global alternative investment group, LDA Capital, enter into a Put Option Agreement for 800 million rubles to help finance the development of Pharmsynthez’s pioneering projects over the next 36 months, including those aimed at combating COVID-19. Both Pharmsynthez and LDA view this capital allocation not only as an investment into the Company but also as a starting point for a long-term strategic partnership to advance Pharmsynthez’s promising projects in the field of innovative pharmaceutical technologies and development of the latest treatments for complex diseases. LDA Capital’s investments will accelerate Pharmsynthez PJSC projects in all aspects. The Company’s business plan until 2025 allows for the introduction of several highly profitable original drugs (Epolong® and other finished dosage forms) to the domestic market, an increase in the production of active pharmaceutical ingredients, and the launch
Global Consumer Brands Unveil World’s First Enzymatically Recycled Bottles24.6.2021 08:00:00 EEST | Press release
The promise of endlessly recycled PET plastic is one step closer today, as the Consortium – Carbios, L’Oréal, Nestlé Waters, PepsiCo and Suntory Beverage & Food Europe – announces the successful production of the world’s first food-grade PET plastic bottles produced entirely from enzymatically recycled plastic. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210623005867/en/ Closing the loop for recycling PET plastic. Photo credit: Jérôme Pallé (Photo: Business Wire) Each Consortium company has successfully manufactured sample bottles – based on Carbios’ enzymatic PET recycling technology – for some of their leading products including: Biotherm®, Perrier®, Pepsi Max®** and Orangina®. Today’s announcement is the culmination of nearly 10 years’ research and development by Carbios to create a new process and supercharge an enzyme naturally occurring in compost heaps that normally breaks down leaf membranes of dead plants. By ada
Vifor Pharma to revise DIAMOND study, readout expected in H2 202124.6.2021 08:00:00 EEST | Press release
Regulatory News: Vifor Pharma Group today announced that the phase-IIIb DIAMOND study has been amended with new and clinically relevant endpoints, including a new primary endpoint of efficacy in potassium management in high-risk heart failure patients treated with guideline-recommended doses of renin-angiotensin aldosterone system inhibitor (RAASi). This decision has been made on the recommendation from the independent study Executive Committee and following the significant impact of COVID-19 on recruitment. Patients with heart failure and chronic kidney disease are among those at the highest risk of severe outcomes of COVID-19 infection. During the pandemic, treatment practices have been adapted to reduce risks of exposure to COVID-19 during hospital visits, disrupting clinical care and impacting the conduct of randomized clinical trials such as the DIAMOND study. This has led to fewer patients enrolled in the trial than anticipated and to a slower incidence of cardio-vascular events.
MYbank’s Use of Digital Technology Leads to Record Growth in Rural Clients24.6.2021 06:42:00 EEST | Press release
MYbank, a leading online private commercial bank and associate of Ant Group, today reported it has served over 20 million clients in rural areas across China as of June 2021, representing a 44.2% year-on-year increase driven by digital credit solutions for rural areas. Since its founding six years ago, MYbank has served more than 40 million SMEs and rural clients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210623005998/en/ Women entrepreneurs in Dangshan County in eastern China’s Anhui Province were able to expand their fruit business with loans from MYbank. (Photo: Business Wire) In the past year, 84% of MYbank’s new rural clients had previously been unable to obtain a business loan, due either to a lack of credit history or collateral. MYbank has provided access to credit for such clients by leveraging technologies such as AI-powered risk management, cloud computing, and remote sensing. For example, by adopting remote
O-RAN ALLIANCE Announces New Specifications and Demos, First Open Test and Integration Centers and Its June 29 Industry Summit24.6.2021 01:22:00 EEST | Press release
O-RAN ALLIANCE welcomes stc as its new operator member, building up the world-wide community of 29 mobile network operators committed to deployment of open and intelligent Radio Access Networks (RAN). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210623005961/en/ O-RAN Logical Architecture (Graphic: Business Wire) 33 New or Updated O-RAN Specifications Released since March 2021 On June 17, 2021, the O-RAN ALLIANCE published another 33 specification documents, including 11 new titles. Among others these new specifications include: Management interface, timing and synchronization for Transport The baseline for Non-Real-Time Radio Intelligent Controller (Non-RT RIC) and Near-Real-Time RIC Architecture and interfaces (E2, A1, F1/X2/Xn) Certification and badging guidelines and parts of end-to-end, inter-operability and conformance testing For more details on the new specifications, please check this O-RAN blog post. To download
Grand Prize Winner Announced in $5M IBM Watson AI XPRIZE Competition23.6.2021 20:30:00 EEST | Press release
XPRIZE, the world’s leader in designing and operating incentive competitions to solve humanity’s grand challenges, and IBM Watson , IBM’s AI technology for business, today announced the Grand Prize Winner in the $5M IBM Watson AI XPRIZE Challenge. First launched in 2016, the five-year global competition looked to accelerate adoption of artificial intelligence (AI) technologies and spark creative, innovative and audacious demonstrations of the technology that are truly scalable to solve societal grand challenges. Winning first place honors is Zzapp Malaria, in second place is Aifred Health , followed by Marinus Analytics . These finalists were selected out of a pool of 10 semifinalists following presentations of their solutions to a panel of judges during an event held at TED headquarters in New York City last year. A $3 million grand prize, $1 million second place prize, and $500k third place prize will be awarded to the teams. In total, over 150 teams throughout the world joined the c
Echodyne Expands Market for Leading CUAS Radar, EchoGuard23.6.2021 19:00:00 EEST | Press release
Echodyne, the radar platform company, announced today substantial enhancements to its industry-leading radars, adding a new radar for international markets, a new product for special operations-type applications, a ruggedized radome, and continuing improvements in software and performance. Together, these product developments represent significant advancements to its breakthrough radar technology, MESA®. With customers in defense, national security, and critical infrastructure protection, Echodyne radars have become a core component for counter-UAS, border security, and base and perimeter 3D surveillance solutions. The products and improvements include: EchoGuard International. The new EchoGuard radar has RoHS3 construction and is compliant with CE Radio Equipment Directive (RED) compliance for EU customers, per Type Examination Certificate per 2014/53/EU Radio Equipment directive. EchoGuard spectrum expansion. Many jurisdictions allow for RadioLocation use at 24.05-24.25 GHz, and Echo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom